NEW YORK CITY, NY / ACCESS Newswire / July 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ:RARE). Investors who purchased Ultragenyx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RARE.
Investigation Details
On July 9, 2025, Ultragenyx and its development partner Mereo BioPharma Group plc issued a press release "announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur "around the end of the year." Following this news, Ultragenyx’s stock price fell $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Ultragenyx securities, you can assist this investigation by visiting the firm’s site: bgandg.com/RARE. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_467528492/2457/2025-07-24T10:01:28